Should a Loop Ileostomy Closure in Rectal Cancer Patients Be Done During or After Adjuvant Chemotherapy?
Overview
Oncology
Affiliations
Background And Objective: The influence of ileostomy closure timing on surgical and oncologic outcome was investigated in patients with locally advanced rectal cancer receiving adjuvant chemotherapy after low anterior resection.
Methods: Consecutive patients diagnosed with T3-4/N+ rectal cancer, treated by neoadjuvant chemoradiation and low anterior resection during 2000-2012 were retrospectively evaluated. Patients undergoing closure during adjuvant chemotherapy (Group A) were compared to patients undergoing closure after completing chemotherapy (Group B).
Results: A total of the 165 patients met inclusion criteria, of whom 104 received adjuvant chemotherapy (25 in Group A and 79 in Group B). The pathologic stage was higher in Group B (P = 0.015). The rates of postoperative complications were similar (16% for Group A and 15% for Group B, P = 0.88), as was hospital stay (mean 5.78 days for Group A and 6.25 days for Group B, P = 0.7). There was no significant difference in recurrence rate and overall survival between the groups.
Conclusions: Referral to ileostomy closure in relation to adjuvant chemotherapy is influenced by pathologic stage. Early referral appears to be reserved to a small number of patients with lower pathologic stage. Timing of ileostomy closure does not change short- or long-term results.
Rizzo G, Ferrara F, Parini D, Pata F, Forni C, Anania G Int J Colorectal Dis. 2025; 40(1):43.
PMID: 39964558 PMC: 11836177. DOI: 10.1007/s00384-025-04827-8.
Tsai K, You J, Huang S, Tsai T, Hsieh P, Lai C Langenbecks Arch Surg. 2023; 408(1):274.
PMID: 37438486 DOI: 10.1007/s00423-023-03014-z.
Cheng H, Shao Y, Lin C, Chiang T, Chen M, Chiu T Tech Coloproctol. 2023; 27(12):1227-1234.
PMID: 36973527 DOI: 10.1007/s10151-023-02790-6.
Naveed S, Banday S, Qari H, Zahoor S, Batoo A, Wahid M Euroasian J Hepatogastroenterol. 2023; 12(2):81-91.
PMID: 36959991 PMC: 10028703. DOI: 10.5005/jp-journals-10018-1382.
Muller S, Weyhe D, Herrle F, Horvath P, Bachmann R, von Ehrlich-Treuenstatt V Trials. 2023; 24(1):76.
PMID: 36726155 PMC: 9890770. DOI: 10.1186/s13063-023-07089-3.